Improving HIV prevention and care for adolescents and young adults in Uganda
Implementation Science to Understand and Design Stakeholder Informed Innovative Interventions to Improve Adolescent and Youth HIV Prevention and Care Continuums in Rural and Urban Uganda
This project will try offering long-acting HIV prevention injections and youth-focused care to help 15–24-year-olds in Uganda prevent HIV and reach viral suppression if they are living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mu-Jhu Care NIH-funded |
| Lab location | 1 site (Kampala, Uganda) |
| Project ID | NIH-11177784 on NIH RePORTER |
What this research studies
You would be part of work that reaches young people in both rural and urban communities across Uganda to find those at higher risk for HIV and connect them to services. For HIV-negative youth, the project will offer long-acting injectable PrEP (cabotegravir) through community-friendly delivery models to reduce the need for daily pills. For youth living with HIV, teams will provide life-stage based support and the SEARCH-Youth package to help improve treatment adherence and viral suppression. The program uses proven interventions in combination with new screening approaches and implementation methods to make services easier for young people to use.
Who could benefit from this research
Good fit: Ideal participants are adolescents and young adults (about 15–24 years old) in Uganda who are at high risk for HIV or are living with HIV and need better support to stay on prevention or treatment.
Not a fit: People outside the 15–24 age range, those not living in participating communities or clinics in Uganda, or individuals with medical reasons that prevent use of cabotegravir may not benefit from this project.
Why it matters
Potential benefit: If successful, the work could make prevention and treatment easier for young people and increase protection against HIV and rates of viral suppression.
How similar studies have performed: Long-acting injectable PrEP has shown strong protection in clinical trials, but delivering it and combining it with youth-focused support in real-world Ugandan settings is newer and less tested.
Where this research is happening
Kampala, Uganda
- Mu-Jhu Care — Kampala, Uganda (Active)
Researchers
- Principal investigator: Musoke, Philippa — Mu-Jhu Care
- Study coordinator: Musoke, Philippa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.